Department of Pharmacy, Xijing Hospital, the Fourth military medical university, Xi'an 710032, Shaanxi, PR China; No. 422 Hospital of PLA, Zhanjiang 524005, Guangdong, PR China.
No. 422 Hospital of PLA, Zhanjiang 524005, Guangdong, PR China.
J Ethnopharmacol. 2015 Jun 20;168:136-45. doi: 10.1016/j.jep.2015.03.063. Epub 2015 Apr 4.
Saponins of many herbs are known to possess anti-cancer effect.
The present study aimed to investigate the growth inhibitory effect of Trillium tschonoskii steroidal saponins in a mouse model of colitis-associated colorectal cancer and a human colorectal cancer cell line HT-29, and isolate some major constituents and evaluate their anti-tumor activity.
Forty male ICR mice were administered with 1, 2-dimethyl-hydrazine (DMH) and dextran sodium sulfate (DSS). Ten mice were given no further treatment, the rest were administered with different doses of TTS (5, 10, 20mg/kg) orally, every three days from the 9th week to the 20th week.
TTS effectively protected ICR mice against DMH/DSS-induced tumorigenesis. The incidence of tumor development was 90% (9/10) in the mice treated with DMH/DSS, but that was reduced to 50% (5/10), 40% (4/10), and 20% (2/10), respectively, in the mice treated with 5%, 10%, and 20% of TTS. Results of Ki-67 staining, TUNEL assay and caspase-3 activity assay revealed that TTS moderately decreased abnormal proliferation and increased apoptosis of colonic epithelial cells. It inhibited the growth and triggered the apoptosis of HT-29 cells, partly through suppressing mitogen-actived protein kinases (MAPKs) and triggering mitochondrial-mediated apoptotic pathway. Three compounds, namely, Paris saponin VII, polyphylloside III and Paris saponin VI, were important active compounds in TTS.
These data suggest that TTS has a potential role in clinical prevention and treatment for colorectal cancer.
许多草药的皂苷已被证明具有抗癌作用。
本研究旨在探讨延龄草甾体皂苷(TTS)在结肠炎相关结直肠癌小鼠模型和人结肠癌细胞系 HT-29 中的生长抑制作用,并分离一些主要成分并评估其抗肿瘤活性。
40 只雄性 ICR 小鼠给予 1,2-二甲基肼(DMH)和葡聚糖硫酸钠(DSS)。10 只小鼠未进行进一步治疗,其余小鼠分别给予 TTS(5、10、20mg/kg)口服,从第 9 周到第 20 周每三天一次。
TTS 可有效保护 ICR 小鼠免受 DMH/DSS 诱导的肿瘤发生。用 DMH/DSS 处理的小鼠中肿瘤发展的发生率为 90%(9/10),但用 5%、10%和 20%的 TTS 处理的小鼠中分别降低至 50%(5/10)、40%(4/10)和 20%(2/10)。Ki-67 染色、TUNEL 检测和 caspase-3 活性检测结果表明,TTS 可适度降低结肠上皮细胞的异常增殖并增加细胞凋亡。它抑制 HT-29 细胞的生长并引发其凋亡,部分通过抑制丝裂原激活蛋白激酶(MAPKs)和触发线粒体介导的凋亡途径。三种化合物,即重楼皂苷 VII、重楼皂苷 III 和重楼皂苷 VI,是 TTS 中的重要活性化合物。
这些数据表明 TTS 可能在结直肠癌的临床预防和治疗中发挥作用。